| Description: |
Muhammad Adrish,1 Jessica K DeMartino,2 Donna Carstens,2 Mandy Jackson,2 Kathleen Wilson,3 Jill Schinkel,3 Joseph Tkacz3 1Baylor College of Medicine, Houston, TX, USA; 2AstraZeneca, Wilmington, DE, USA; 3Inovalon, Bowie, MD, USACorrespondence: Joseph Tkacz, Inovalon, 4321 Collington Road, Bowie, MD, 20716, USA, Email joseph.tkacz@inovalon.comPurpose: This real-world evidence study sought to evaluate the effectiveness of benralizumab on reducing both asthma and COPD exacerbations among patients with a diagnosis of asthma and concomitant COPD.Patients and Methods: This study was a non-interventional, single-arm, retrospective database analysis of the MORE2 Registry® and the 100% Medicare Fee-for-Service (FFS) claims databases from 2017– 2022. Inclusion criteria were as follows: 1) prescription claim for benralizumab and ≥ 1 refill within 90 days (earliest claim=index date), 2) 12 months of database enrollment preceding (baseline) and following (follow-up) the index date, 3) medical claims with diagnoses of asthma and COPD during the baseline period, and 4) presence of ≥ 2 asthma exacerbations during the baseline period. Percent change in the annual rates of both asthma and COPD exacerbations were assessed from the baseline to follow-up, with paired t-tests used to examine statistically significant differences. Subgroup analyses were also conducted among the subset of patients with blood eosinophil levels, and by payer type.Results: A total of 2894 patients with asthma and concomitant COPD were included. Following initiation of benralizumab, the mean (SD) number of total asthma exacerbations decreased by 39.2% (from 4.0 (2.2) to 2.4 (2.4) exacerbations/year; p < 0.001), while COPD exacerbations decreased by 45.6% (from 3.6 (2.5) to 1.9 (2.2) exacerbations/year; p < 0.001). The proportion of patients receiving systemic corticosteroids decreased by 11.4% from 100% to 88.6% (p < 0.001). Subgroup analyses revealed that patients with the highest eosinophil levels (≥ 300 eosinophils/μL) ... |